Subscribe Now Subscribe Today
Science Alert
 
FOLLOW US:     Facebook     Twitter
Blue
   
Curve Top
International Journal of Pharmacology
  Year: 2015 | Volume: 11 | Issue: 4 | Page No.: 387-393
DOI: 10.3923/ijp.2015.387.393
Structure-Activity-Relationship Study of the Novel p21/waf1 Inhibitor for Anti-Cancer Agents against Renal Cell Carcinoma
See-Hyoung Park

Abstract:
The p21/waf1, especially cytoplasmic or phosphorylated p21/waf1, is one of cancer prognostic marker and known to have the anti-apoptotic function in renal cell carcinoma. Thus, it would be a good therapeutic option to impair the anti-apoptotic activity of p21/waf1 in renal cell carcinoma by small molecule inhibitors. In this study, we are trying to find more potent small molecule inhibitors derived from the previous candidates to bind and block the anti-apoptotic function of p21/waf1. After synthesizing the 24 new derivatives that are modified in their two imidazole chain, it has been successfully found that the No. 13 lead compound has the most cytotoxicity by MTT assay as well as p21 attenuating activity in ACHN and A498 cells. Moreover, the cytotoxicity of No. 13 was increased by the relatively low dose of doxorubicin treatment, a kind of conventional chemotherapies which can help to reduce the side-effect induced from the high dose use of doxorubicin treatment in patients with renal cell carcinoma.
 [Fulltext PDF]   [Fulltext HTML]   [XML: Abstract + References]   [References]   [View Citation]  [Report Citation]
How to cite this article:

See-Hyoung Park , 2015. Structure-Activity-Relationship Study of the Novel p21/waf1 Inhibitor for Anti-Cancer Agents against Renal Cell Carcinoma. International Journal of Pharmacology, 11: 387-393.

DOI: 10.3923/ijp.2015.387.393

URL: https://scialert.net/abstract/?doi=ijp.2015.387.393

 
COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 

Curve Bottom